Kristyna Paradis, DO
Internal Medicine · Debary, FLNPI 1285686824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 33.3% of the total. 2025 is the largest year on record at $391, 4.0 times the $98 reported in 2019.
Across 19 payments — averaging $61.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$390
- AbbVie$266
- Zimmer Biomet$177
- Penumbra, Inc.$145
- Z-medica, LLC$98
- Pfizer$51
- plus $44 from 3 others
Across 2 payments — averaging $7250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$15K
What the payments were for
- Consulting fees$988%
- Food & beverage$1,07292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $390 |
| AbbVie | 5 | $266 |
| Zimmer Biomet | 2 | $177 |
| Penumbra, Inc. | 1 | $145 |
| Z-medica, LLC | 1 | $98 |
| Pfizer | 3 | $51 |
| Bausch Health US, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$380
- Indigo System$145
- QULIPTA$121
- ROSA$111
How this compares
$1,170 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 16 | $278 |
| Atorvastatin Calcium | 15 | $246 |
| Prednisone | 14 | $20 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Debary
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.